Cargando…

Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer

The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Tanabe, Shihori, Boonstra, Eger, Hong, Taehun, Quader, Sabina, Ono, Ryuichi, Cabral, Horacio, Aoyagi, Kazuhiko, Yokozaki, Hiroshi, Perkins, Edward J., Sasaki, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671144/
https://www.ncbi.nlm.nih.gov/pubmed/38003016
http://dx.doi.org/10.3390/genes14112073
_version_ 1785149381516722176
author Tanabe, Shihori
Boonstra, Eger
Hong, Taehun
Quader, Sabina
Ono, Ryuichi
Cabral, Horacio
Aoyagi, Kazuhiko
Yokozaki, Hiroshi
Perkins, Edward J.
Sasaki, Hiroki
author_facet Tanabe, Shihori
Boonstra, Eger
Hong, Taehun
Quader, Sabina
Ono, Ryuichi
Cabral, Horacio
Aoyagi, Kazuhiko
Yokozaki, Hiroshi
Perkins, Edward J.
Sasaki, Hiroki
author_sort Tanabe, Shihori
collection PubMed
description The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers. Since diffuse-type stomach adenocarcinoma, which has epithelial–mesenchymal transition (EMT)-like characteristics, is more malignant than intestinal-type stomach adenocarcinoma, the gene expression and molecular networks in diffuse- and intestinal-type stomach adenocarcinomas were analyzed. Analysis of carboplatin revealed the causal network in diffuse large B-cell lymphoma. The upstream regulators of the molecular networks of cisplatin-treated lung adenocarcinoma included the anti-cancer drug trichostatin A (TSA), a histone deacetylase inhibitor. The upstream regulator analysis of cisplatin revealed an increase in FAS, BTG2, SESN1, and CDKN1A, and the involvement of the tumor microenvironment pathway. The molecular networks were predicted to interact with several microRNAs, which may contribute to the identification of new drug targets for drug-resistant cancer. Analysis of oxaliplatin, a platinum drug, revealed that the SPINK1 pancreatic cancer pathway is inactivated in ischemic cardiomyopathy. The study showed the importance of the molecular networks of anti-cancer drugs and tumor microenvironment in the treatment of cancer resistant to anti-cancer drugs.
format Online
Article
Text
id pubmed-10671144
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106711442023-11-13 Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer Tanabe, Shihori Boonstra, Eger Hong, Taehun Quader, Sabina Ono, Ryuichi Cabral, Horacio Aoyagi, Kazuhiko Yokozaki, Hiroshi Perkins, Edward J. Sasaki, Hiroki Genes (Basel) Brief Report The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers. Since diffuse-type stomach adenocarcinoma, which has epithelial–mesenchymal transition (EMT)-like characteristics, is more malignant than intestinal-type stomach adenocarcinoma, the gene expression and molecular networks in diffuse- and intestinal-type stomach adenocarcinomas were analyzed. Analysis of carboplatin revealed the causal network in diffuse large B-cell lymphoma. The upstream regulators of the molecular networks of cisplatin-treated lung adenocarcinoma included the anti-cancer drug trichostatin A (TSA), a histone deacetylase inhibitor. The upstream regulator analysis of cisplatin revealed an increase in FAS, BTG2, SESN1, and CDKN1A, and the involvement of the tumor microenvironment pathway. The molecular networks were predicted to interact with several microRNAs, which may contribute to the identification of new drug targets for drug-resistant cancer. Analysis of oxaliplatin, a platinum drug, revealed that the SPINK1 pancreatic cancer pathway is inactivated in ischemic cardiomyopathy. The study showed the importance of the molecular networks of anti-cancer drugs and tumor microenvironment in the treatment of cancer resistant to anti-cancer drugs. MDPI 2023-11-13 /pmc/articles/PMC10671144/ /pubmed/38003016 http://dx.doi.org/10.3390/genes14112073 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Tanabe, Shihori
Boonstra, Eger
Hong, Taehun
Quader, Sabina
Ono, Ryuichi
Cabral, Horacio
Aoyagi, Kazuhiko
Yokozaki, Hiroshi
Perkins, Edward J.
Sasaki, Hiroki
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title_full Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title_fullStr Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title_full_unstemmed Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title_short Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
title_sort molecular networks of platinum drugs and their interaction with micrornas in cancer
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671144/
https://www.ncbi.nlm.nih.gov/pubmed/38003016
http://dx.doi.org/10.3390/genes14112073
work_keys_str_mv AT tanabeshihori molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT boonstraeger molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT hongtaehun molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT quadersabina molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT onoryuichi molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT cabralhoracio molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT aoyagikazuhiko molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT yokozakihiroshi molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT perkinsedwardj molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer
AT sasakihiroki molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer